Ofatumumab versus Teriflunomide in Multiple Sclerosis, PMID: 32757523
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study, PMID: 29695594
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, PMID: 24881631
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab, PMID: 33092190
Ofatumumab, PMID: 33091123
Ofatumumab, PMID: 26648645
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis, PMID: 33090003
Ofatumumab, PMID: 31643960
Ofatumumab, PMID: 20481657
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL, PMID: 30287523
Ofatumumab, PMID: 20068404
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab, PMID: 30842083
Ofatumumab, PMID: 29999646
Ofatumumab (Kesimpta) for multiple sclerosis, PMID: 33451176
The use of ofatumumab in the treatment of B-cell malignancies, PMID: 28850252
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study, PMID: 24453078
More on Ofatumumab for TTP, PMID: 29619817
More on Ofatumumab for TTP, PMID: 29617588
Ofatumumab, PMID: 20118960
Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation, PMID: 32306087
Ofatumumab for post-transplant lymphoproliferative disorder, PMID: 32413419
Ofatumumab in the treatment of non-Hodgkin's lymphomas, PMID: 26043777
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study, PMID: 28029326
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial, PMID: 32589978
Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis, PMID: 28580841
Ofatumumab in the treatment of chronic lymphocytic leukemia, PMID: 20683500
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia, PMID: 32855756
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, PMID: 21342032
Ofatumumab for the treatment of chronic lymphocytic leukemia, PMID: 25882470
Ofatumumab (Arzerra) for CLL, PMID: 20585286
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, PMID: 31512258
Adult Acute Lymphoblastic Leukemia, PMID: 27814839
Ofatumumab, a human anti-CD20 monoclonal antibody, PMID: 20109133
Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia, PMID: 21896924
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models, PMID: 23873847
Ofatumumab for treating chronic lymphocytic leukemia: a safety profile, PMID: 26566719
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK, PMID: 21609654
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia, PMID: 24947256
Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients, PMID: 28790834
Management of Waldenström macroglobulinemia in 2020, PMID: 33275726
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?, PMID: 32619884
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness, PMID: 31980477
Refractory pemphigus vulgaris successfully treated with ofatumumab, PMID: 32715065
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia, PMID: 21030349
Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies, PMID: 22830942
Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia, PMID: 21595596
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab, PMID: 26855591
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study, PMID: 31801940
Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience, PMID: 33327846
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies, PMID: 20458041
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study., PMID:40505538
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation., PMID:40472290
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264
Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis., PMID:40367683
Interventions for idiopathic steroid-resistant nephrotic syndrome in children., PMID:40337980
A Case of Refractory Hiccups and Numbness as the Initial Presentation of Multiple Sclerosis., PMID:40330392
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates., PMID:40303316
Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report., PMID:40278334
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database., PMID:40235349
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505
Subcutaneous ofatumumab in recurrent focal segmental glomerulosclerosis after kidney transplantation., PMID:40212825
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function., PMID:40180777
Reconstitution of CXCR3+ CCR6+ Th17.1-Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis., PMID:40164501
Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report., PMID:40154217
Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review., PMID:40145095
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425
Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model., PMID:40130187
Recurrent late-onset neutropenia after ofatumumab treatment in a case of multiple sclerosis., PMID:40122879
Effective treatment of immune mediated peripheral neuropathy with Ofatumumab - A case report., PMID:40121773
Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study., PMID:40107181
Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study., PMID:40083393
Effect of Treatment on Steroidome in Women with Multiple Sclerosis., PMID:40076462
Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis., PMID:40050009
[Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis]., PMID:40047834
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study., PMID:39991981
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis., PMID:39974306
Comparison of B-cell depletion versus natalizumab for treatment of multiple sclerosis: A semi-supervised causal analysis., PMID:39974119
Evolving Patterns of Initial RRMS Treatment in Finland (2013-2022): Insights From a Nationwide Multiple Sclerosis Register., PMID:39935206
Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis., PMID:39933126
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis., PMID:39917326
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system., PMID:39917308
Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series., PMID:39845958
Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study., PMID:39835156
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice., PMID:39834277
Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis., PMID:39833702
Multiple sclerosis and sickle cell anemia: when two worlds collide., PMID:39808347
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies., PMID:39805178
Ofatumumab for treating autoimmune nodopathy., PMID:39800963
Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy., PMID:39787234
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells., PMID:39774793
Ofatumumab-exposed breastfeeding in multiple sclerosis patients., PMID:39757874
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia., PMID:39755895
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches., PMID:39742715
Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab., PMID:39737186
Exploring Public Interest in Multiple Sclerosis and Its Treatment Measures in the United States: A Google Trends Analysis., PMID:39734957
Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection., PMID:39729629
For research use only. Not for human or drug use.
